<DOC>
	<DOCNO>NCT02281448</DOCNO>
	<brief_summary>Single centre , two-way crossover , randomise , open-label study 20 healthy female volunteers.The volunteer receive oral single-dose combine contraceptive contain oral daily dose 1200 mg BIA 2-093</brief_summary>
	<brief_title>Effect BIA 2-093 Pharmacokinetics Combined Oral Contraceptive .</brief_title>
	<detailed_description>Single centre , two-way crossover , randomise , open-label study 20 healthy female volunteers.The volunteer receive oral single-dose combine contraceptive contain 30 μg ethinyloestradiol 150 μg levonorgestrel two occasion ─ pre-treatment oral daily dose 1200 mg BIA 2-093 15 day separate washout period least 3 week .</detailed_description>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Eslicarbazepine acetate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Contraceptives , Oral , Combined</mesh_term>
	<criteria>Premenopausal female ; Able willing give write informed consent ; Aged 18 40 year , inclusive ; Not pregnant breastfeeding ; Body mass index ( BMI ) 19 30 kg/m2 , inclusive ; Healthy determine medical history , physical examination , complete neurological examination , vital sign , 12lead ECG ; Clinical laboratory test clinically acceptable result screen admission first period ; Negative test HBsAg , antiHCV Ab HIV1 HIV2 Ab screening ; Negative test drug abuse screening ; Nonsmoker smoke less 10 cigarette equivalent per day ; Agreed either practice abstinence use doublebarrier intrauterine device screen followup visit ; Negative pregnancy test screen admission first period . Had contraindication use oral contraceptive ; Had experience notable adverse event oral contraceptive ; Had history alcoholism drug abuse ; Had relevant history presence respiratory , gastrointestinal , renal , hepatic , haematological , lymphatic , neurological , cardiovascular , psychiatric , musculoskeletal , genitourinary , immunological , dermatological , endocrine , connective tissue diseases disorder ; Had acute gastrointestinal symptom time screen admission first period ; Had significant infection inflammatory process time screen admission first period ; Had relevant surgical history ; Had relevant family history ; Had history relevant drug hypersensitivity ( e.g. , carbamazepine oxcarbazepine ) ; Had use relevant prescription overthecounter medication within 2 week ofadmission first period ; Consumed 14 unit alcohol week ; Had participate clinical trial within 3 month prior screen ; Had previously receive BIA 2093 ; Had donate receive blood blood product within 2 month prior screen ; Was unlikely cooperate requirement study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>